Genmab — Januar 2026
-
Vi er ned med 4-5%
-
*nede
-
SHB: Överdriven marknadsreaktion på Genmabs Epkinly-studie https://borsvarlden.com/artiklar/shb-overdriven-marknadsreaktion-pa-genmabs-epkinly-studie
-
Genmabs kursklø efter nye data er overdreven mener Handelsbanken https://proinvestor.com/investornyt/1404483/genmabs-kursklo-efter-nye-data-er-overdreven-mener-handelsbanken
-
in separate news, the AbbVie trial is on hold for now, until final resolution of the related U.S. International Trade Commission (ITC) investigation https://www.pacermonitor.com/public/case/57357486/AbbVie_Inc_v_Genmab_AS_et_al
-
Hvis man ikke har fulgt med i, hvad kombinationsbehandlingerne har vist, så kan dette link anbefales. https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-multiple-clinical-trials-showing-treatment
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind